JP Morgan Downgrades Mereo BioPharma Group to Underweight
JP Morgan analyst Priyanka Grover downgrades Mereo BioPharma Group (NASDAQ:MREO) from Neutral to Underweight.
Read original at benzingaStocks · News reference
Mereo BioPharma Announces Option And License Agreement With Zydus Unit Sentynl For US Rights To Alvelestat In AATD-LD; Eligible For $40M Upfront On Option Exercise, Up To $435M In Milestones
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 12:05 PM
- Checked
- Aug 11, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Mereo BioPharma Group plc (MREO)
Filed: 2026-08-19 AccNo: 0001193125-26-356168 Size: 218 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Read original at edgar12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
Read original at benzinga12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Read original at benzinga